Reference

1. Pascale R, Giannella M, Bartoletti M, Viale P, Pea F. Use of meropenem in treating carbapenem-resistant Enterobacteriaceae infections. Expert Review of Anti-infective Therapy. 2019;17(10):819–27. doi:10.1080/14787210.2019.1673731
2. Rodríguez-Villodres Á, Martín-Gandul C, Peñalva G, Guisado-Gil AB, Crespo-Rivas JC, Pachón-Ibáñez ME, et al. Prevalence and risk factors for multidrug-resistant organisms colonization in long-term care facilities around the world: A Review. Antibiotics. 2021;10(6):680. doi:10.3390/antibiotics10060680
3. . Jia X-Q, Pang F, Chen J-Z, Jiang L-X. Prevalence and clinical distribution of multidrug-resistant bacteria (3537 isolates) in a tertiary chinese hospital (January 2012–December 2013). Pathologie Biologie. 2015;63(1):21–3. doi:10.1016/j.patbio.2014.12.002
4. 1. Lodise TP, Echols R, Wang W, Corvino F, Cai B. 1191. prevalence and microbiology of carbapenem resistance among six gram-negative pathogens in bloodstream infections in US hospitals, 2010–2015. Open Forum Infectious Diseases. 2018;5(suppl_1). doi:10.1093/ofid/ofy210.1024
5. Anyanwu, P.E. et al. (2017) ‘Exploring the role of socioeconomic factors in the development and spread of anti-malarial drug resistance: A qualitative study’, Malaria Journal, 16(1). doi:10.1186/s12936-017-1849-1.
6. . Fletcher S. Understanding the contribution of environmental factors in the spread of antimicrobial resistance. Environmental Health and Preventive Medicine. 2015;20(4):243–52. doi:10.1007/s12199-015-0468-0
7.  Bhando T, Casius A, Uppalapati SR, Pathania R. Unravelling mechanisms of meropenem induced persistence facilitates identification of GRAS compounds with anti-persister activity against acinetobacter baumannii. 2020; doi:10.1101/2020.07.31.231936
8.  Ouedraogo AS, Jean Pierre H, Bañuls AL, Ouédraogo R, Godreuil S. Emergence and spread of antibiotic resistance in West Africa : Contributing factors and threat assessment. Médecine et Santé Tropicales. 2017;27(2):147–54. doi:10.1684/mst.2017.0678
9. Chen Y-Y, Hsieh Y-C, Gong Y-N, Liao W-C, Li S-W, Chang IY-F, et al. Genomic insight into the spread of meropenem-resistant streptococcus pneumoniae spain23f-st81, Taiwan. Emerging Infectious Diseases. 2020;26(4):711–20. doi:10.3201/eid2604.190717
10.  Hocking L, Ali G-C, d’Angelo C, Deshpande A, Stevenson C, Virdee M, et al. A rapid evidence assessment exploring whether antimicrobial resistance complicates non-infectious health conditions and healthcare services, 2010–20. JAC-Antimicrobial Resistance. 2021;3(4). doi:10.1093/jacamr/dlab171
11.  Judd WR, Ratliff PD, Hickson RP, Stephens DM, Kennedy CA. Clinical and economic impact of meropenem resistance in pseudomonas aeruginosa–infected patients. American Journal of Infection Control. 2016;44(11):1275–9. doi:10.1016/j.ajic.2016.04.218
12.  Eagye KJ, Kuti JL, Nicolau DP. Risk factors and outcomes associated with isolation of meropenem high-level-resistant pseudomonas aeruginosa. Infection Control & Hospital Epidemiology. 2009;30(8):746–52. doi:10.1086/603527
13.  Martin SJ, Micek ST, Wood GC. Antimicrobial resistance: Consideration as an adverse drug event. Critical Care Medicine. 2010;38. doi:10.1097/ccm.0b013e3181de0c26
14. Weinstein RA. Antibiotic resistance in hospitals and intensive care units: The problem and potential solutions. Seminars in Respiratory and Critical Care Medicine. 2003;24(1):113–20. doi:10.1055/s-2003-37922
15.  Tapalski DV, Timoshkova EV, Petrovskaya TA, Osipkina OV, Karpov IA. Microbiological efficiency of the combinations of two carbapenems against antibiotic resistant Klebsiella pneumoniae strains. Russian Clinical Laboratory Diagnostics. 2021;66(5):304–9. doi:10.51620/0869-2084-2021-66-5-304-309
16. Abed M, Yousuf S. A review on meropenem. Research Journal of Pharmacy and Technology. 2021;5034–8. doi:10.52711/0974-360x.2021.00878
17. Ooi N, Lee VE, Chalam-Judge N, Newman R, Wilkinson AJ, Cooper IR, et al. Restoring carbapenem efficacy: A novel carbapenem companion targeting metallo-?-lactamases in carbapenem-resistant Enterobacterales. Journal of Antimicrobial Chemotherapy. 2020;76(2):460–6. doi:10.1093/jac/dkaa455
18. Song X, Wu Y, Cao L, Yao D, Long M. Is meropenem as a monotherapy truly incompetent for meropenem-nonsusceptible bacterial strains? A pharmacokinetic/pharmacodynamic modeling with Monte Carlo Simulation. Frontiers in Microbiology. 2019;10. doi:10.3389/fmicb.2019.02777
19. . Park J-M, Yang K-S, Chung Y-S, Lee K-B, Kim J-Y, Kim S-B, et al. Clinical outcomes and safety of meropenem–colistin versus meropenem–tigecycline in patients with carbapenem-resistant Acinetobacter baumannii pneumonia. Antibiotics. 2021;10(8):903. doi:10.3390/antibiotics10080903
20. Alosaimy S, Lagnf AM, Morrisette T, Scipione MR, Zhao JJ, Jorgensen SC, et al. Real-world, multicenter experience with Meropenem-Vaborbactam for gram-negative bacterial infections including carbapenem-resistant enterobacterales and pseudomonas aeruginosa. Open Forum Infectious Diseases. 2021;8(8). doi:10.1093/ofid/ofab371
21. García-Rodríguez JF, Bardán-García B, Peña-Rodríguez MF, Álvarez-Díaz H, Mariño-Callejo A. Meropenem Antimicrobial Stewardship Program: Clinical, economic, and antibiotic resistance impact. European Journal of Clinical Microbiology & Infectious Diseases. 2018;38(1):161–70. doi:10.1007/s10096-018-3408-2
22. Avendano EE, Raman G, Chan J, McCann E. Burden of carbapenem non-susceptible infections in high-risk patients: Systematic Literature Review and meta-analysis. Antimicrobial Resistance & Infection Control. 2020;9(1). doi:10.1186/s13756-020-00858-8
23. Bartsch SM, McKinnell JA, Mueller LE, Miller LG, Gohil SK, Huang SS, et al. Potential economic burden of carbapenem-resistant Enterobacteriaceae (CRE) in the United States. Clinical Microbiology and Infection. 2017;23(1). doi:10.1016/j.cmi.2016.09.003
24. Maragakis LL, Perencevich EN, Cosgrove SE. Clinical and economic burden of antimicrobial resistance. Expert Review of Anti-infective Therapy. 2008;6(5):751–63. doi:10.1586/14787210.6.5.751
25.  Schmier JK, Hulme Lowe CK. Economic burden and healthcare resource utilization associated with multi-drug resistant Acinetobacter baumannii: A Structured Review of the literature. Journal of Pharmaceutical Care & Health Systems. 2016;3(2). doi:10.4172/2376-0419.1000155
26. Chacón-González C, Rivera-Salgado D, Brenes-Chacón H, Naranjo-Zuñiga G, Ávila-Aguero ML. Use of meropenem in a tertiary pediatric hospital in Costa Rica and its role in the era of antimicrobial stewardship. Cureus. 2021; doi:10.7759/cureus.15809
27. Russell CD, Laurenson IF, Evans MH, Mackintosh CL. Tractable targets for meropenem-sparing antimicrobial stewardship interventions. JAC-Antimicrobial Resistance. 2019;1(2). doi:10.1093/jacamr/dlz042
28. Stultz JS, Arnold SR, Shelton CM, Bagga B, Lee KR. Antimicrobial stewardship impact on pseudomonas aeruginosa susceptibility to meropenem at a tertiary pediatric institution. American Journal of Infection Control. 2019;47(12):1513–5. doi:10.1016/j.ajic.2019.05.001
29.  Qadri H. Novel strategies to combat the emerging drug resistance in human pathogenic microbes. Current Drug Targets. 2021;22(12):1424–36. doi:10.2174/18735592mteyonze24
30. Dutta TK. Alternative therapeutic approaches in the era of antimicrobial resistance: An overview. Indian Journal of Animal Health. 2020;59(1):23. doi:10.36062/ijah.59.1.2020.23-28
31. Alam MM, Islam M, Wahab A, Billah M. Antimicrobial resistance crisis and combating approaches. Journal of Medicine. 2019;20(1):38–45. doi:10.3329/jom.v20i1.38842
32.  Petty L, Henig O, Patel T, Pogue J, Kaye K. Overview of meropenem-vaborbactam and newer antimicrobial agents for the treatment of carbapenem-resistant enterobacteriaceae. Infection and Drug Resistance. 2018;Volume 11:1461–72. doi:10.2147/idr.s150447
33.  Imchen M, Moopantakath J, Kumavath R, Barh D, Tiwari S, Ghosh P, et al. Current trends in experimental and computational approaches to combat antimicrobial resistance. Frontiers in Genetics. 2020;11. doi:10.3389/fgene.2020.563975
34. Reddy N, Girdhari L, Shungube M, Gouws AC, Peters BK, Rajbongshi KK, et al. Neutralizing carbapenem resistance by co-administering meropenem with novel ?-lactam-metallo-?-lactamase inhibitors. Antibiotics. 2023;12(4):633. doi:10.3390/antibiotics12040633
35.  Tarazi Z, Roos N, Page T, Griffith D. 615. Pharmacodynamics (PD) of the beta-lactamase inhibitor XERUBORBACTAM when administered in combination with meropenem. Open Forum Infectious Diseases. 2022;9(Supplement_2). doi:10.1093/ofid/ofac492.667
36. Arer V, Kar D. Biochemical exploration of ?-lactamase inhibitors. Frontiers in Genetics. 2023;13. doi:10.3389/fgene.2022.1060736
37. Khan AS, Dancer SJ, Humphreys H. Priorities in the prevention and control of multidrug-resistant Enterobacteriaceae in hospitals. Journal of Hospital Infection. 2012;82(2):85–93. doi:10.1016/j.jhin.2012.06.013
38. Kamel NA, Elsayed KM, Awad MF, Aboshanab KM, El Borhamy MI. Multimodal interventions to prevent and control carbapenem-resistant Enterobacteriaceae and extended-spectrum ?-lactamase producer-associated infections at a tertiary care hospital in Egypt. Antibiotics. 2021;10(5):509. doi:10.3390/antibiotics10050509
39. Carbapenem-resistant enterobacteriaceae: A strategic roadmap for Infection Control–Corrigendum. Infection Control & Hospital Epidemiology. 2017;38(9):1136–1136. doi:10.1017/ice.2017.141
40. Varghese R, Basu S, Neeravi A, Pragasam A, Aravind V, Gupta R, et al. Emergence of meropenem resistance among cefotaxime non-susceptible streptococcus pneumoniae: Evidence and challenges. Frontiers in Microbiology. 2022;12. doi:10.3389/fmicb.2021.810414
41. Dar OA, Hasan R, Schlundt J, Harbarth S, Caleo G, Dar FK, et al. Exploring the evidence base for national and regional policy interventions to combat resistance. The Lancet. 2016;387(10015):285–95. doi:10.1016/s0140-6736(15)00520-6
42. Rungsitsathian K, Wacharachaisurapol N, Nakaranurack C, Usayaporn S, Sakares W, Kawichai S, et al. Acceptance and outcome of interventions in a meropenem de?escalation antimicrobial stewardship program in Pediatrics. Pediatrics International. 2021;63(12):1458–65. doi:10.1111/ped.14703